Bio
Dr Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI).
Danny was previously Executive Director, Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. He was also Programme Director for the Singapore Biodesign programme, where his team set up programmes to develop talent for medtech technology development and commercialisation. Previously, Danny also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre. In this role, where he and his team were responsible for setting up a brand new centre for biotherapeutics development.
Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas. Danny has deep experience in diabetes therapeutics programmes, including insulins development. He established a high quality diabetes research capability at LNUS, which has enabled LNUS to perform niche studies in the support of Lilly portfolio, including several pivotal registration studies for the U.S. Food and Drug Administration (FDA).
Education
Bachelor of Medicine, Bachelor of Surgery
National University of Singapore, Singapore